 <h1>Nydrazid Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>isoniazid</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about isoniazid. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Nydrazid.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to isoniazid: solution, tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intramuscular route (Solution)</p><p>Severe and sometimes fatal hepatitis has been reported with isoniazid therapy and may occur even after many months of treatment. The risk for hepatitis increases with advancing age, concomitant alcohol use, chronic liver disease, and injection drug use. Patients given isoniazid should be carefully monitored and interviewed at monthly intervals. For persons 35 and older, in addition to monthly symptom reviews, hepatic enzymes (specifically, AST and ALT (formerly SGOT and SGPT, respectively) should be measured prior to starting isoniazid therapy and periodically throughout treatment. An increased risk of fatal hepatitis associated with isoniazid has been reported in women, particularly black and Hispanic women. The risk may also be increased during the post partum period. More careful monitoring should be considered in these groups, possibly including more frequent laboratory monitoring.</p><p class="blackboxWarning-title">Oral route (Tablet; Syrup)</p><p>Severe and sometimes fatal hepatitis has been reported with isoniazid therapy and may occur even after many months of treatment. The risk for hepatitis increases with advancing age, concomitant alcohol use, chronic liver disease, and injection drug use. Patients given isoniazid should be carefully monitored and interviewed at monthly intervals. For persons 35 and older, in addition to monthly symptom reviews, hepatic enzymes (specifically, AST and ALT (formerly SGOT and SGPT, respectively) should be measured prior to starting isoniazid therapy and periodically throughout treatment. An increased risk of fatal hepatitis associated with isoniazid has been reported in women, particularly black and Hispanic women. The risk may also be increased during the post partum period. More careful monitoring should be considered in these groups, possibly including more frequent laboratory monitoring.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, isoniazid (the active ingredient contained in Nydrazid) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking isoniazid:</p><p>
<i>More common</i>
</p><ul>
<li>Clumsiness or unsteadiness</li>
<li>dark urine </li>
<li>loss of appetite</li>
<li>nausea or vomiting</li>
<li>numbness, tingling, burning, or pain in hands and feet</li>
<li>unusual tiredness or weakness </li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blurred vision or loss of vision, with or without eye pain</li>
<li>convulsions (seizures)</li>
<li>fever and sore throat</li>
<li>joint pain</li>
<li>mental depression</li>
<li>mood or other mental changes</li>
<li>skin rash</li>
<li>unusual bleeding or bruising </li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of isoniazid may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>stomach pain</li>
</ul><p>
<i>For injection form</i>
</p><ul>
<li>Irritation at the place of injection</li>
</ul><p>Dark urine and yellowing of the eyes or skin (signs of liver problems) are more likely to occur in patients over 50 years of age.</p><p>
<!-- end solution, tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to isoniazid: intramuscular solution, oral syrup, oral tablet</i></p><h3>General</h3><p>The most commonly reported side effects included mild and transient elevation of serum transaminase levels, peripheral neuropathy, and hepatitis.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Peripheral neuropathy usually occurred with doses over 5 mg/kg.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Mild and transient elevation of serum transaminase levels (up to 20%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatitis</p>
<p><b>Frequency not reported</b>: Abnormal liver function, bilirubinemia, jaundice, mild liver dysfunction, severe hepatitis/fatal hepatitis<sup>[Ref]</sup></p><p>Mild and transient elevation in serum transaminases usually occurred in the first 1 to 6 months of treatment, but could occur at any time during treatment.  Transaminase levels returned to normal with continued treatment in most cases.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Peripheral neuropathy</p>
<p><b>Frequency not reported</b>: Convulsions, memory impairment, optic neuritis, paresthesia of the feet/hands, toxic encephalopathy<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (0.01% to 0.1%): Eosinophilia systemic symptoms, toxic epidermal necrolysis</p>
<p><b>Frequency not reported</b>: Allergic skin reaction, alopecia, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, erythema multiforme, exfoliative dermatitis, exfoliative skin eruptions, maculopapular skin eruptions, morbilliform skin eruptions, purpura, purpuric skin eruptions, rash, skin eruptions<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Agranulocytosis, anemia, aplastic anemia, eosinophilia, hemolytic anemia, lymphadenopathy, sideroblastic anemia, thrombocytopenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Anorexia, hyperglycemia, metabolic acidosis, pellagra, pyridoxine deficiency<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Frequency not reported</b>: Epigastric distress, nausea, pancreatitis, vomiting<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Fatigue, fever, malaise, weakness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Psychosis, toxic psychosis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Lupoid syndrome, systemic lupus erythematosus-like syndrome<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Optic atrophy<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Bilirubinuria<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Vasculitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Gynecomastia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Rheumatic syndrome<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Local irritation<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Nydrazid (isoniazid)" Apothecon Inc, Princeton, NJ. </p><p id="ref_2">2. "Product Information. Isoniazid (isoniazid)." Barr Laboratories Inc, Pomona, NY. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ. </p><p id="ref_5">5. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Nydrazid (isoniazid)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: hydrazide derivatives</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Mycobacterium kansasii</li>
<li>Tuberculosis, Active</li>
<li>Tuberculosis, Latent</li>
<li>Tuberculosis, Prophylaxis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to isoniazid: intramuscular solution, oral syrup, oral tablet</i></p><h3>General</h3><p>The most commonly reported side effects included mild and transient elevation of serum transaminase levels, peripheral neuropathy, and hepatitis.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Peripheral neuropathy usually occurred with doses over 5 mg/kg.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Mild and transient elevation of serum transaminase levels (up to 20%)</p><p><b>Uncommon</b> (0.1% to 1%): Hepatitis</p><p><b>Frequency not reported</b>: Abnormal liver function, bilirubinemia, jaundice, mild liver dysfunction, severe hepatitis/fatal hepatitis<sup>[Ref]</sup></p><p>Mild and transient elevation in serum transaminases usually occurred in the first 1 to 6 months of treatment, but could occur at any time during treatment.  Transaminase levels returned to normal with continued treatment in most cases.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Peripheral neuropathy</p><p><b>Frequency not reported</b>: Convulsions, memory impairment, optic neuritis, paresthesia of the feet/hands, toxic encephalopathy<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (0.01% to 0.1%): Eosinophilia systemic symptoms, toxic epidermal necrolysis</p><p><b>Frequency not reported</b>: Allergic skin reaction, alopecia, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, erythema multiforme, exfoliative dermatitis, exfoliative skin eruptions, maculopapular skin eruptions, morbilliform skin eruptions, purpura, purpuric skin eruptions, rash, skin eruptions<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Agranulocytosis, anemia, aplastic anemia, eosinophilia, hemolytic anemia, lymphadenopathy, sideroblastic anemia, thrombocytopenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Anorexia, hyperglycemia, metabolic acidosis, pellagra, pyridoxine deficiency<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Frequency not reported</b>: Epigastric distress, nausea, pancreatitis, vomiting<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Fatigue, fever, malaise, weakness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Psychosis, toxic psychosis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Lupoid syndrome, systemic lupus erythematosus-like syndrome<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Optic atrophy<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Bilirubinuria<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Vasculitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Gynecomastia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Rheumatic syndrome<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Local irritation<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Nydrazid (isoniazid)" Apothecon Inc, Princeton, NJ. </p><p id="ref_2">2. "Product Information. Isoniazid (isoniazid)." Barr Laboratories Inc, Pomona, NY. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ. </p><p id="ref_5">5. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about Nydrazid (isoniazid)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: hydrazide derivatives</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Mycobacterium kansasii</li>
<li>Tuberculosis, Active</li>
<li>Tuberculosis, Latent</li>
<li>Tuberculosis, Prophylaxis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>